SCHEMBL30714550

SCHEMBL30714550

CN1CCC(NC(=O)c2c3cc(OCc4ccccn4)ccc3nn2C)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DRD4 P21917 1/20 0.46
SLC6A5 Q9Y345 5/20 0.44
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
HTR3A P46098 2/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
MAPK14 Q16539 2/20 0.40
SMO Q99835 2/20 0.40
SSTR4 P31391 2/20 0.39
MET P08581 1/20 0.39
POLR1A O95602 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714672 0.90 RAB9A (0.43) ALDH1A1DRD4HTR3AMAPK14SMO
SCHEMBL26868541 0.87 ACSS2 (0.40) DRD4HTR3AMAPK14SMO
SCHEMBL31539894 0.86 SMO (0.40) HTR3AMAPK14SMOMET
SCHEMBL30714657 0.85 SLC6A5 (0.43) KDM4EALDH1A1HPGDHSD17B10SLC6A5
SCHEMBL26696013 0.84 PDE5A (0.41) HSD17B10DRD4HTR3AMAPK14SMO
SCHEMBL30714573 0.83 MET (0.40) KDM4EALDH1A1HPGDHSD17B10HTR3A
SCHEMBL30714705 0.83 MET (0.40) KDM4EALDH1A1HPGDHSD17B10HTR3A
SCHEMBL30714713 0.83 HTR3A (0.51) SLC6A5HTR3A
SCHEMBL26868378 0.82 GRM5 (0.42) ALDH1A1MAPK14SMO
SCHEMBL26868537 0.82 DGAT2 (0.43) DRD4HTR3AMAPK14SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 KDM4E 3992/4885ALDH1A1 1658/4885HPGD 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.